加载中
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
前收盘价
US$165.69
+US$4.40 · +2.73%
盘中时间采用ET。市场数据可能有所延迟。
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
日内区间
当前US$165.69
52周区间
当前US$165.69
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
58
合理估值
情绪
60
多空交织
风险
33
中等风险
动量
72
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
日内区间
当前US$165.69
52周区间
当前US$165.69
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 5.07亿 USD | 3.83亿 USD | 3.15亿 USD | 2.83亿 USD | 2.94亿 USD |
| 销货成本 | 1.14亿 USD | 9402.7万 USD | 7557.5万 USD | 6897.9万 USD | 6662.7万 USD |
| 毛利 | 3.93亿 USD | 2.89亿 USD | 2.39亿 USD | 2.14亿 USD | 2.27亿 USD |
| 研究与开发 | 1.51亿 USD | 1.36亿 USD | 1.39亿 USD | 1.23亿 USD | 1.01亿 USD |
| 销售、一般及管理费用 | 3.29亿 USD | 2.63亿 USD | 2.24亿 USD | 1.93亿 USD | 1.79亿 USD |
| 营业费用 | 4.8亿 USD | 4.12亿 USD | 3.68亿 USD | 2.96亿 USD | 2.6亿 USD |
| 利息收入 | 1071.4万 USD | 1110.5万 USD | 916.4万 USD | 237.5万 USD | 128.8万 USD |
| 利息支出 | 463.5万 USD | 1004万 USD | 1363.3万 USD | 1372万 USD | 1337.2万 USD |
| 折旧和摊销 | 4234.5万 USD | 3992.2万 USD | 3797.8万 USD | 3594.6万 USD | 3442.1万 USD |
| 营业利润 | −8673.3万 USD | −1.22亿 USD | −1.29亿 USD | −8231.3万 USD | −3287.2万 USD |
| 净利润 | −1.88亿 USD | −1.46亿 USD | −1.35亿 USD | −9919.5万 USD | −4959.3万 USD |
公司数据更新于 2026年10月11日。
报告持有此股票敞口的交易所交易基金。
iShares Core S&P Small-Cap ETFIJR5.68亿0.55%1031.91亿 USD0.06%US$137.55+0.17%
Vanguard Morningstar Total Stock Market ETFVTI3.18亿0.01%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM2.45亿0.31%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB2.31亿0.12%1853亿 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK1.32亿0.29%447亿 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF1.23亿0.13%954亿 USD0.05%US$235+0.80%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM8740.91万0.55%158.4亿 USD0.03%US$53.45+0.17%
iShares Russell 2000 Growth ETFIWO8592.11万0.62%139.17亿 USD0.24%US$356.78+0.94%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMiShares Russell 2000 Growth ETFIWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
